Ultragenyx Pharmaceutical Inc
For the period ended Dec 31, 2023. Filed Feb 21, 2024.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2023 · Filed Feb 21, 2024
RARE$16.41+6.4%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Statements of Comprehensive Loss
| Year Ended December 31, | |||
|---|---|---|---|
| 2023 | 2022 | 2021 | |
| Net loss | $(606,639) | $(707,421) | $(454,025) |
| Other comprehensive income (loss): | |||
| Foreign currency translation adjustments | 239 | (724) | (550) |
| Unrealized gain (loss) on available-for-sale securities | 6,981 | (4,445) | (1,543) |
| Other comprehensive income (loss): | 7,220 | (5,169) | (2,093) |
| Total comprehensive loss | $(599,419) | $(712,590) | $(456,118) |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.